Squamous Non-small Cell Lung Cancer
Pipeline by Development Stage
Drug Modality Breakdown
Oncology is a $53.9B market in consolidation, dominated by a handful of megacap players with blockbuster franchises approaching patent expiration.
Key Trends
- Heavy patent cliff exposure (REVLIMID $3.9B LOE 2028, JAKAFI $1.9B LOE 2028)
- Kinase inhibitors and immunomodulatory agents dominate spend; limited diversification in top 10
- Clinical trial volume remains exceptionally high (29,145 trials) but concentration in Phase 1-2 signals early-stage pipeline challenges
Career Verdict
Strong near-term opportunity for R&D and medical affairs roles, but competitive landscape and patent cliff urgency favor specialists over generalists.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (apixaban) | Bristol Myers Squibb | $18.3B | 34% | Launch | Stable | 14.9yr |
| 2 | FARXIGA (dapagliflozin) | AstraZeneca | $4.3B | 8% | Peak | Stable | 15.3yr |
| 3 | REVLIMID (lenalidomide) | Bristol Myers Squibb | $3.9B | 7% | LOE Approaching | Declining | 1.7yr |
| 4 | XTANDI (enzalutamide) | Astellas | $2.6B | 5% | Peak | Stable | 10.6yr |
| 5 | IMBRUVICA (ibrutinib) | AbbVie | $2.4B | 4% | Peak | Stable | 8.8yr |
Drug Class Breakdown
concentrated in single product
single dominant product
multi-product class, competitive
facing near-term patent cliff
prostate cancer specialty
niche hematologic oncology
near-term LOE exposure
Career Outlook
StableOncology remains a premium therapeutic area but faces structural headwinds: top 10 products account for >80% of spend, patent cliffs loom (REVLIMID 2028), and late-stage pipeline thinness suggests slower near-term growth. However, high trial volume and consolidation create demand for specialized expertise in regulatory, clinical operations, and lifecycle management. Pharma professionals with kinase inhibitor, immunomodulatory, or ADC experience are in highest demand.
Breaking In
Entry-level candidates should target CROs (Thermo Fisher, IQVIA), emerging biotech (BeiGene, BeOne), or contract manufacturing; oncology specialization requires demonstrated domain knowledge.
For Experienced Professionals
Experienced professionals should focus on lifecycle/patent strategy roles (high salary, low headcount) or pivot to emerging modalities (ADCs, bispecifics) to avoid commoditization in crowded kinase inhibitor space.
In-Demand Skills
Best For
Hiring Landscape
Oncology hiring is actively concentrated at Thermo Fisher Scientific (CRO/CDMO services, 559 jobs), AstraZeneca (208 jobs), and emerging biotech players like BeiGene (185 jobs). Commercial roles dominate (412 jobs, $136K avg) but R&D positions offer the highest salary premium ($199K avg, 347 roles). Patent cliff urgency is creating acute demand for regulatory, CMC, and lifecycle management expertise.
Top Hiring Companies
By Department
Strong near-term hiring momentum, especially in CRO/CDMO and emerging biotech; Medical Affairs offers highest compensation but limited headcount.
Competitive Landscape
8 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 11,791 patients across 50 trials
A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India
Study of Nivolumab for Advanced Cancers in India
A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer
An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers
An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma
A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread
A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer
A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer
Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy in Subjects With Squamous Non-small Cell Lung Cancer
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma
A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer
A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia
Early Switch Maintenance vs Delayed Second-line Nivolumab in Advanced Stage Squamous Non-small Cell Lung Cancer (NSCLC) Patients (EDEN Trial)
An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma
A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma
A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks
A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma
A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen
A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis
CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer
A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer
Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab
Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer
An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer
Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma
EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC
Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC
An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo)
Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer
BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab
Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor
Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric Cancer
Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL
Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC.
Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC
Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants
CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma
A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer
Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer
Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma
Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma
Related Jobs in Oncology
Senior Medical Director, Clinical Development
Research Associate/Scientist I, Cell Biology
Associate Director, External Quality
Aseptic Manufacturing Technician I- Day Shift A [Contract to Hire]
Sr. Manager, IT Risk and Compliance - Foster City, CA
Project Leadership – Biotech (clinical trials) – Oncology - Home Based - (Future Needs)
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.